NYSE:BMYPharmaceuticals
A Look At Bristol Myers Squibb (BMY) Valuation After Earnings Beat And Strong 2026 Guidance
Bristol-Myers Squibb (BMY) has moved back into the spotlight after reporting fourth quarter and full year 2025 results, combining higher profitability, flat annual revenue and fresh guidance that exceeded Wall Street expectations.
See our latest analysis for Bristol-Myers Squibb.
The earnings release and 2026 guidance have fed into a sharp rebound in sentiment, with a 90 day share price return of 31.17% and a 1 year total shareholder return of 14.55%, indicating that momentum has recently...